Feb 24, 2021 10:41am Novartis' first DTC campaign for relapsing MS drug Kesimpta debuted in January, five months after it got an FDA nod. (Novartis) Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable relapses” and “disability progression” pop up around a young woman as she goes about her day. But another issue that pops up on screen—infusion days—may cause some drama itself. That's because it's describing rival infusion treatments for MS, including Kesimpta’s chief competitor Ocrevus, a Roche drug that also works by targeting CD20-expressing B-cells.